Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Ilumya, also known by its generic name Tildrakizumab, is a prescription medication used to treat moderate to severe plaque psoriasis in adults who may benefit from systemic therapy or phototherapy. This advanced biologic medication specifically targets the IL-23 protein, a key contributor in the pathogenesis of psoriasis, helping to reduce the inflammation and plaque formation associated with the condition.
Ilumya is an injectable medication, administered subcutaneously, and is designed to be used over long periods for sustained symptom management. Its development and approval are based on rigorous clinical trials demonstrating both efficacy and safety, providing new hope for patients dealing with the chronic, often debilitating symptoms of plaque psoriasis. Before you buy Leqvio injection, it is crucial that you talk to your healthcare provider about potential side effects and Leqvio cost.
| Fact Table | |
|---|---|
| Formula | Monoclonal antibody |
| License | FDA approved |
| Bioavailability | 77-88% |
| Legal status | Prescription Drug |
| Chemical Name | Tildrakizumab |
| Elimination half-life | 23 days |
| Dosage (Strength) | 100 mg/mL solution for subcutaneous injection |
| Pregnancy | Caution advised |
| Brands | Ilumya |
| Protein binding | Not determined (monoclonal antibody) |
| PubChem CID | Not available (biologic) |
| MedlinePlus | a618036 |
| ChEBI | Not applicable |
| ATC code | L04AC17 |
| DrugBank | DB13852 |
| KEGG | D11063 |
| Routes of administration | Subcutaneous |
Ilumya is administered by subcutaneous injection. Ilumya injections should be given by a healthcare professional or should be administered under their supervision once proper training in subcutaneous injection techniques has been provided.
Ilumya dosing: 100 mg (one injection) at weeks 0, 4, and then every 12 weeks thereafter.
The active ingredient in Ilumya is Tildrakizumab.
Patients considering Ilumya should discuss their full medical history with their healthcare provider, especially if they have any infections or an immune system condition. Before starting treatment, patients should be evaluated for tuberculosis (TB). Ilumya may increase the risk of infections, and any active infection should be treated prior to initiating therapy with Ilumya.
Ilumya is not recommended for use in patients who are hypersensitive to Tildrakizumab or any of the other ingredients in the medication.
Ilumya may interact with other medications, particularly those that affect the immune system. It is crucial to inform your healthcare provider of all medications you're using, including prescriptions, over-the-counter drugs, vitamins, and herbal supplements. Specifically, avoid using other biologic drugs that suppress the immune system while taking Ilumya unless specifically directed by your healthcare provider.
The most common side effects associated with Ilumya include:
What is Ilumya?
Ilumya (generic name: tildrakizumab-asmn) is a prescription medication that is a monoclonal antibody. It is used to treat certain autoimmune conditions by targeting specific proteins in the body’s immune system.
What is Ilumya used for?
Ilumya is primarily used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
How does Ilumya work?
Ilumya works by targeting and inhibiting interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, Ilumya reduces the inflammation and rapid skin cell growth associated with plaque psoriasis.
How is Ilumya administered?
Ilumya is administered via subcutaneous injection. The initial dose is followed by a second dose after four weeks, and then maintenance doses are given every 12 weeks. The injections are usually administered by a healthcare professional.
Does Ilumya cause hair loss?
Hair loss is not a common side effect of Ilumya. However, individual experiences with medications can vary, and any new or worsening symptoms should be discussed with a healthcare provider.
Does Ilumya cause weight gain?
Weight gain is not a known or commonly reported side effect of Ilumya. Patients should monitor any significant changes in their weight and report them to their healthcare provider.
How long does it take for Ilumya to work?
The effectiveness of Ilumya can vary among individuals. Some patients may start to see improvement in their symptoms within a few weeks, but it can take up to 12 weeks or longer for others to notice significant benefits.
What are the side effects of Ilumya?
Common side effects of Ilumya include:
Serious side effects are rare but can include:
Patients should discuss potential side effects with their healthcare provider.
Does Ilumya treat psoriatic arthritis?
Yes, Ilumya is also used to treat psoriatic arthritis, an inflammatory arthritis associated with psoriasis. It helps reduce joint pain and inflammation, improving physical function and quality of life for those with this condition.
